Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2012) A. Cervantes et al.   CLINICAL CANCER RESEARCH

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

(2012) E. C. Dees et al.   CLINICAL CANCER RESEARCH

The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents

(2011) Deborah R. Wysong et al.   CELL CYCLE

Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays

(2011) M. G. Manfredi et al.   CLINICAL CANCER RESEARCH

Chromosome missegregation in human cells arises through specific types of kinetochore-microtubule attachment errors

(2011) S. L. Thompson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

(2010) E. Claire Dees et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

(2010) A. Chakravarty et al.   CANCER RESEARCH

MLN8054, an Inhibitor of Aurora A Kinase, Induces Senescence in Human Tumor Cells Both In vitro and In vivo

(2010) J. J. Huck et al.   MOLECULAR CANCER RESEARCH

Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics

(2010) T. Macarulla et al.   MOLECULAR CANCER THERAPEUTICS

Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

(2008) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE